Effects of Cardiorespiratory Rehabilitation on the Right Ventricle in Pulmonary Hypertension
Rehab-HTP
1 other identifier
interventional
12
1 country
1
Brief Summary
Clinical improvement has been demonstrated after cardiorespiratory rehabilitation in patients with pulmonary hypertension. Rehabilitation is therefore now part of the recommendations for good practice. However, no data is available to elucidate the mechanism of this improvement: an improvement in myocardial reserve or an improvement in peripheral muscular capacity? The main objective of this study is to evaluate the difference in right ventricular contractile reserve before and after cardiorespiratory rehabilitation during stress ultrasound in pulmonary hypertension in 10 patients with pulmonary hypertension.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 12, 2018
CompletedFirst Posted
Study publicly available on registry
January 19, 2018
CompletedStudy Start
First participant enrolled
June 12, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 5, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 5, 2020
CompletedAugust 29, 2023
August 1, 2023
1.1 years
January 12, 2018
August 28, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Improvement of the subpulmonary ITS at effort >20% (presence of a right ventricular contractile reserve) defined by the improvement of the ITS or integral subpulmonary time-speed)
4 months
Study Arms (1)
Patients with pulmonary hypertension
OTHERInterventions
A stress echocardiography will be performed in addition to the traditional patient care
Eligibility Criteria
You may qualify if:
- Major patients
- Proven pulmonary hypertension: PAPm ≥ 25mmHg, known PH
- Group 1,3,4 or 5 of the pulmonary hypertension classification
- Clinical stability \> 1 month clinically determined by clinician
- NYHA II or III class
- Signature of informed consent form following appropriate information
- Patient affiliated to the Social Security System
You may not qualify if:
- Associated left heart disease
- Complex congenital heart disease
- Acoustic window which does not allow the echocardiography to be performed correctly
- Permanent cardiac arrhythmia
- NYHA IV class and NYHA I class
- Inability to perform at least a minimal effort on an ergometer
- Unstabilized acute coronary syndrome
- Compensatory heart failure
- Disturbances of ventricular rhythm veins, may not be narrowed.
- Prevalence of high-risk embolic intracardiac thrombus
- Prevalence of high-risk embolic intracardiac thrombus
- Preference of a medium to high abundance peericard-like thinning.
- Venous thromboembolic venous thromboembolic disease (\> 3 months)
- Left ventricular ejector obstruction (severe and/or symptomatic)
- Persons under guardianship, under curatorship, protected by law
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Pasteur
Nice, 06002, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pamela MOCERI, PH
Centre Hospitalier Universitaire de Nice
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 12, 2018
First Posted
January 19, 2018
Study Start
June 12, 2018
Primary Completion
July 5, 2019
Study Completion
July 5, 2020
Last Updated
August 29, 2023
Record last verified: 2023-08